Orphan drugs have become a focal point in India’s healthcare discussions, particularly following the National Policy for Rare Diseases (NPRD) established in 2021. This policy aimed to create a framework for diagnosing and treating rare diseases, yet challenges remain in developing, pricing, and accessing these critical medications. Unlike the comprehensive support seen in the United States and the European Union, India is still navigating the complexities of orphan drug legislation and patient care.
About Orphan Drugs
Orphan drugs are specifically designed to treat rare diseases, which often affect a small portion of the population. The definition of a rare disease varies globally; for instance, in the U.S., it is classified as affecting fewer than 200,000 individuals, while the European Union considers a disease rare if it impacts fewer than 1 in 10,000 people. In India, however, there is no formal definition, complicating the identification of orphan drugs and the needs of affected patients.
Classification of Orphan Drugs
Orphan drugs can be categorised based on the diseases they target and their regulatory status. Commonly, these include genetic disorders like cystic fibrosis, rare cancers such as neuroblastoma, and metabolic disorders like Gaucher’s disease. The NPRD classifies rare diseases into three groups – Group 1 includes curable conditions needing one-time interventions; Group 2 encompasses diseases requiring long-term management; and Group 3 involves conditions with available but costly treatments.
Criteria for Orphan Drug Designation
To qualify for orphan drug designation, a drug must meet specific criteria, which may differ across countries. Generally, the disease must have low prevalence, and the drug should either lack existing treatments or provide advantages over them. Developers need to present scientific evidence demonstrating the drug’s potential efficacy, which can be submitted at various stages of development.
Challenges in India
Despite the global push for orphan drug development, India faces hurdles. The high costs associated with research and development pose a substantial barrier, as these drugs often target small patient populations. Additionally, the limited number of patients complicates clinical trials, leading to prolonged development timelines. The exorbitant prices of orphan drugs make them inaccessible for many in low- and middle-income settings, where treatments can cost several crores annually.
Need for Financial Incentives
To overcome these challenges, India must implement financial incentives to stimulate orphan drug development. Establishing a national rare disease registry is crucial for accurate prevalence data, which can guide targeted treatment development. Moreover, introducing tax breaks, research grants, and subsidies would encourage pharmaceutical companies to invest in orphan drug research. Regulating orphan drug pricing and providing government subsidies could enhance accessibility for patients.
Global Comparisons
In contrast to India, countries like the U.S. and those in the EU have established robust frameworks that incentivise orphan drug development. The Orphan Drug Act in the U.S. offers market exclusivity, tax credits, and fee waivers, creating a supportive environment for pharmaceutical innovation. India’s lack of similar incentives hampers its ability to attract investment in orphan drug research, limiting treatment options for rare disease patients.
Last Modified: November 5, 2024Questions for UPSC:
- Discuss the significance of orphan drugs in the treatment of rare diseases in India.
- What are the major challenges faced in the development and accessibility of orphan drugs in India?
- How does India’s approach to orphan drug regulation compare with that of the United States and the European Union?
- Evaluate the role of financial incentives in promoting orphan drug development in India.
- Explain the classification of rare diseases under the National Policy for Rare Diseases.